Nimoral (nimorazole)

Tumor volume, p16, and CSC markers are potential biomarkers for HDF for patients with HNSCC treated with (C-)RT. Lower expression of CSC in p16+ OPSCC may contribute to better tumor control.

Nimorazole combined with RCTx improved local tumor control in some but not in all HNSCC xenografts. We identified prognostic biomarkers with the potential for translation to patients with HNSCC.

Treatment was primary curative IMRT-based (C-)RT (66-68Gy/33-34fx 6 fx/wk (+/- cisplatin 40mg/m2 weekly)) and nimorazole. Conclusion Tumor volume was prognostic for the non-HPV-driven tumors only. In contrast to volume, the level of CSC was prognostic in OPSCCp16+, which may benefit in selection of pts for individualized treatment.

Concomitant chemotherapy was cisplatin (40 mg/m2 weekly). Seventy percent of patients treated with primary (C)RT received concurrent nimorazole...Loco-regional failures are described in relation to planned CTVs. The loco-regional control was acceptable and comparable to primary head and neck SCC in other sites.